Avinger, Inc. (AVGR) Research

Avinger, Inc. is a commercial-stage medical technology firm that develops, manufactures, and markets sophisticated image-guided, catheter-based systems. These devices are utilized by physicians both domestically and internationally to treat patients suffering from Peripheral Arterial Disease (PAD). Central to Avinger's offerings is its proprietary lumivascular platform. This innovative technology integrates Optical Coherence Tomography (OCT) visualization directly into interventional catheters, providing real-time, intravascular imaging to guide doctors during PAD procedures. The company's lumivascular product suite includes the Lightbox imaging consoles, as well as the Ocelot family of catheters, which are specifically designed to help physicians penetrate complete arterial blockages. Additionally, the Pantheris is an image-guided atherectomy device enabling precise removal of plaque from affected arteries. Avinger also offers its earlier-generation Chronic Total Occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2. These employ a unique rotational spinning technique, allowing physicians to switch between passive and active modes when navigating difficult CTOs. Furthermore, the company is developing IMAGE-BTK, a specialized solution for treating PAD lesions located below-the-knee. Avinger's advanced medical devices are sold to a specialized clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists. The company was founded in 2007 and is headquartered in Redwood City, California.

Open Avinger, Inc. (AVGR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.